Neuroscience Clinical Trial Experience

The central nervous system affects physical and behavioral health in untold ways. Unraveling the field’s complexity requires an understanding that comes only from experience.

prcom_Asset 1ARROW

Breaking barriers in neuroscience

A nuanced approach to a uniquely complex field

These are exciting times for neuroscience drug development as we help the most innovative sponsors unlock the mysteries of the central nervous system (CNS) and bring breakthrough therapies to millions of patients in need. From our pioneering work in rare diseases to the growing field of consciousness-expanding psychedelic drugs – where our experience in licensing, regulation, and investigator and therapist training is helping shape a new class of therapies – our neuroscience clinical research and regulatory professionals are committed to supporting you at any point of your development journey.

Having performed more than 350 projects across CNS research in the past five years, our team of experts offer a diverse range of psychiatric and neurological experience to provide the best possible regulatory and scientific, medical, and operational delivery for the success of your asset. As your novel therapy moves from concept to commercialization, we have the hands-on experience and knowledgeable staff to provide the precise approach you need to anticipate and overcome obstacles along the way.

Why choose Premier?
  • Our work has touched more than 50,000 patients afflicted by just about every major central nervous system disorder
  • More than half of our work is in rare diseases
  • We have a history of breakthrough work, including the first post-traumatic stress disorder study in military veterans

PREMIER PERSPECTIVE

Disease-modifying therapies in Parkinson’s disease

Researchers have made many attempts at disease modification as they pursue breakthroughs in treating Parkinson’s disease, but so far without success. Why have these efforts failed, and what’s next?

PREMIER INSIGHT

Positive results delivered ahead of time

With unanticipated interest in these pivotal Phase 3 studies, Premier Research needed to line up and train the right resources while collaborating effectively with the central laboratory, data manager, and other participants.

Featured Resources

WEBINAR

WEBINAR

Disease-Modifying Therapies in Alzheimer’s and Neurodegenerative Disorders

White Paper

White Paper

The Role of Long-Acting Injectable Antipsychotics in Schizophrenia

Article

Article

Patient Recruitment and Engagement in Neuroscience Studies

Neuroscience Experts

Krista Armstrong, Ph.D.

Krista Armstrong, Ph.D.

Senior Vice President, Neuroscience
Andreas Schreiner, M.D.

Andreas Schreiner, M.D.

Senior Vice President, Medical Affairs Neuroscience & Analgesia
Adam Simmons

Adam Simmons

Executive Director, Clinical Program Strategy

Connect with us

Ready to get started? So are we. Drop us a line to learn more about how we can help.